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The pathogenesis of coronavirus disease 2019 (COVID-19) may be envisaged as the dynamic interaction
between four vicious feedback loops chained or happening at once. These are the viral loop, the hyperinflam-
matory loop, the non-canonical renin-angiotensin system (RAS) axis loop, and the hypercoagulation loop.
Severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 lights the wick by infecting alveolar epithe-
lial cells (AECs) and downregulating the angiotensin converting enzyme-2 (ACE2)/angiotensin (Ang-17)/
Mas1R axis. The viral feedback loop includes evading the host’s innate response, uncontrolled viral replica-
tion, and turning on a hyperactive adaptative immune response. The inflammatory loop is composed of the
exuberant inflammatory response feeding back until exploding in an actual cytokine storm. Downregulation
of the ACE2/Ang-(17)/Mas1R axis leaves the lung without a critical defense mechanism and turns the scale
to the inflammatory side of the RAS. The coagulation loop is a hypercoagulable state caused by the interplay
between inflammation and coagulation in an endless feedback loop. The result is a hyperinflammatory and
hypercoagulable state producing acute immune-mediated lung injury and eventually, adult respiratory dis-
tress syndrome.









Adult distress respiratory syndrome.
B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)“Effects vary with the conditions which bring them to pass, but
laws do not vary. Physiological and pathological states are ruled
by the same forces; they differ only because of the special condi-
tions under which the vital laws manifest themselves”
Claude Bernard
(18131878)1. Introduction
In December 2019, a new epidemic disease appeared in the
Huanan Seafood Wholesale Market, Wuhan, Hubei Province, China. It
was characterized by an upper respiratory tract infection rapidly
evolving to bilateral pneumonia and eventually respiratory failure
[1]. The etiologic agent was a new coronavirus which was named
SARS-CoV-2, whereas the disease was called COVID-19 [2]. The dis-
ease quickly expanded from its original nucleus in Hubei and byMarch 11, 2020 the WHO declared it as a pandemic. As of June 23,
2020, COVID-19 has affected 188 countries around the world, with
9.131.445 confirmed cases worldwide and a death toll of 472.856 [3].
Early in the course of the pandemic, clinicians and researchers
realized that full-blown COVID-19 evolved in at least three phases:
the first phase with cough, fever, wheezing, fatigue, headache, diar-
rhea, and dyspnea, reminiscent of an upper tract respiratory infec-
tion. The second phase, with the rapid appearance of bilateral
pneumonia, infiltrates with variable degrees of hypoxemia, and Omit
in the third phase in which some patients developed respiratory fail-
ure leading to death [4]. Around 80% of people have SARS-COV-2
infection asymptomatic or with mild to moderate illness, mostly
restricted to the upper and conducting airways. The other 20% will
develop symptomatic infection needing hospital admission, and 5%
will require ventilatory support in the Intensive Care Unit (ICU) [5].
The clinical phases of the infection reflect the pathogenic events
starting with the virus gaining access to the lungs. The clinical mani-
festations and pathogenic events of any infectious disease, and
COVID-19 in particular, should be viewed in the light of the damage-
response framework in which several factors and forces may tip the
scales to the host or pathogen side [6]. Therefore, sometimes the
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2 P. Domingo et al. / EBioMedicine 58 (2020) 102887pathogen could be a mere initiator more than an actual perpetrator
and it is the host’s forces unchained by the pathogen’s presence those
which are to cause tissue and organ damage.
Herein, we will review the current knowledge about COVID-19
pathogenesis, and how SARS-CoV-2 infection and the host response
depict the different scenarios of COVID-19. We foresee four interplay-
ing vicious loops, namely a viral loop, a defective non-canonical RAS
loop, an inflammatory loop, and a coagulation loop (Fig. 1).
With b-coronaviruses sharing most of their genome and struc-
ture, it seems quite logical that they can also share mechanisms of
pathogenicity and that the host responses to these shared elements
will be somewhat comparable. Therefore, in some aspects of the pres-
ent review, we refer to other zoonotic coronaviruses to explain path-
ogenic events that can take place in COVID-19.2. The first horseman: a sneaky virus
SARS-CoV-2 is a previously unknown b-coronavirus which shows
88% identity to the sequences of two bat-derived SARS-like coronavi-
ruses, 79.5% identity to SARS-CoV, and about 50% identity to Middle
East Respiratory Syndrome (MERS)-CoV [2]. The genome of SARS-
CoV-2 is a positive-sense, single-stranded RNA with a size of 29.9 kb,
containing at least ten open reading frames (ORFs) [7]. Recently, non-
canonical ORFs and at least 41 RNA modifications with an unknown
function, were identified [7]. The first ORFs represent two-thirds of
the viral RNA. They are translated into two large polyproteins, which
are later processed into 16 non-structural proteins (nsp1 to nsp16)
that form the viral complex replicase-transcriptase [7]. These nsps
rearrange endoplasmic reticulum into double-membrane vesicles,
where viral replication and transcription take place [8,9]. The other
third of the genome encodes four main structural proteins; spike (S),
envelope (E), nucleocapsid (N), and membrane (M) proteins, and sev-
eral accessory proteins whose functions are currently unknown but
unrelated to viral replication [10].
SARS-CoV-2, like SARS-CoV, requires the ACE2 as a receptor to
enter the cells [11,12]. Coronavirus S protein is a determinant of virus
entry into host cells by binding the envelope spike glycoprotein to its
cellular receptor ACE2 [13,14]. Although it was initially thought that
SARS-CoV achieved entry by membrane fusion, a critical proteolytic
cleavage at SARS-CoV S protein, mediated by type II transmembrane
serine protease (TMPRSS2), brings about membrane fusion and viral
infectivity [15]. After the virus entry, the RNA genome is released
into the cytoplasm and translated into two polyproteins and struc-
tural proteins [16].
The survival of SARS-CoV in host cells is eased by strategies to
evade the immune response. The evolutionarily conserved microbial
structures called pathogen-associated molecular patterns (PAMPs)
are recognized by pattern recognition receptors (PRRs) such as toll-
like receptor (TLRs), retinoic acid-inducible gene-I (RIG-I)-like recep-
tors, nucleotide-binding oligomerization domain (NOD)-like recep-
tors, and C-type lectin-like receptors [17]. SARS-CoV induces the
Fig. 1. The four hurtful feedback loops in the pathophysiology of COVID-19.
Schema representing the most remarkable pathophysiological events involved in each of the four vicious feedback loops and the complex interactions established between
them. Intersections between circles represent interaction between loops. The central circle colored in red means the final events of the physiopathologic cascade. The vicious viral
loop is depicted in green, the hyperinflammatory loop is colored in orange, the ACE2/Ang-(17) loop is colored in yellow, and the hypercoagulation loop is colored in purple.
IFN = interferon; PAMPs = Pathogen-associated molecular patterns; DAMPs = Damage-associated molecular patterns; SARS-CoV-2 = Severe acute respiratory syndrome Corona-
virus 2; AECs = Alveolar epithelial cells; ECs = Endothelial cells; ACE2 = Angiotensin-converting enzyme 2; Ang-(17) = Angiotensin 17; ACE = Angiotensin-converting enzyme;
Ang II = Angiotensin II; NO = Nitric oxide; PGI2 = Prostacyclin; MF = Macrophages; PMNs = Polymorphonuclear neutrophils; DAD = Diffuse alveolar damage; ALI = Acute lung injury;
ARDS = Adult respiratory distress syndrome; EOD = End-organ disease.
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replicate in these vesicles [18]. Furthermore, several structural and
nsps encoded by SARS-CoV and MERS-CoV antagonize antiviral
innate immune response. Interferon (IFN) and interferon-stimulated
genes (ISGs) responses are counteracted by nsp1, nsp3 macrodomain,
nsps-deubiquitinase, and ORF3b, ORF6, and ORF9, thus overthrowing
antiviral response [19-24]. nsp1 inhibits IFN responses by three
mechanisms, inactivation of host translational machinery, degrada-
tion of host mRNAs, and inhibiting signal transducer and activator of
transcription 1 (STAT1) phosphorylation [25,26]. Part of the nsp3 is apapain-like protease that antagonizes IFN and cytokine production
by blocking phosphorylation of IFN regulation factor 3 (IRF3) and dis-
rupting NF-KB signaling [24]. Nsp7 and nsp15 are also IFN antago-
nists by an unknown mechanism [24]. ORF3b exerts IFN antagonism
through inhibition of IFNb induction by transcription factors IRF3
and NF-KB, whereas ORF6 antagonizes IFN by inhibiting signaling
through the JAK-STAT pathway [24]. M and N proteins flatten IFN
signaling by inhibiting TANK-binding kinase 1 (TBK1)/IKB kinase e
(IKKE), and the negative regulation of TRAF3/6-TBK1-IRF3/NF-KB/
AP1 signals [25,26].
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tion resulting in increased viral PAMPs and DAMPs that additionally
dampen IFN signaling and stimulate PRRs to induce an aberrant
inflammatory response. The replicative capacity of SARS-CoV-2 is
3.20 folds more than that of SARS CoV in infected human lung tissue
without significantly inducing types I, II, and III IFNs [27]. Since innate
immunity is the frontline defense against SARS-CoV-2, a slow and
poorly coordinated response may result in higher viral replication.
This sequence of events, namely AECs infection, IFN signaling inhibi-
tion, and free viral replication depicts the viral vicious loop (Fig. 1).
3. The second horseman: a gathering storm
SARS-CoV-2 infects primarily airway and alveolar AECs, especially
type II pneumocytes, the cells that produce alveolar surfactant and
are predecessors of type I pneumocytes. However, it can infect any
cell expressing the receptor ACE2, such as endothelial cells, pericytes,
vascular smooth muscle cells, macrophages, fibroblasts, T-cells, cardi-
omyocytes, enterocytes, basal cell epidermal cells, and epithelial
tubular distal cells [28-30]. SARS-CoV-2, in the face of unchecked rep-
lication because of dampened innate immunity, can replicate in high
titres early after the infection [28,31,32].Fig. 2. Physiopathology of acute lung injury in SARS-CoV-2 infection (COVID-19).
SARS-CoV-2 infects primarily type II pneumocytes through binding to the ACE2 recepto
attract monocyte-macrophages and neutrophils to the alveolar space, which secrete addition
releasing large amounts of proinflammatory factors. Endothelial cells are infected, overe
undergo apoptosis, which, together with alveolar cell apoptosis, increases vascular leakage a
dysfunction activate coagulation cascades through tissue factor expression, platelet activatio
endothelial-alveolar barrier further promotes vascular leakage resulting in interstitial and a
to increasing vasoconstriction, inflammatory signals, endothelial dysfunction, vascular leakag
SARS-CoV-2 = Severe acute respiratory syndrome Coronavirus 2; TNF-a = Tumor necrosi
MIP-1A = Macrophage inhibitory protein 1A; IL-6 = Interleukin 6; IL-1b = Interleukin 1 beta;High viral replication in AECs induces cytopathic effects, as shown
by the necropsy findings of multinucleated cells (syncytia), cyto-
plasmic viral inclusions, and apoptosis, an ultimate cellular response
to stop virus replication [33,34]. These events are followed by the
production of increased levels of proinflammatory cytokines and che-
mokines by AECs [35,36]. Moreover, SARS-CoV nucleocapsid activates
interleukin-6 (IL-6) expression in lung epithelial cells via cellular
transportation of nuclear factor kappa B (NF-KB) [37]. Massive infil-
tration of inflammatory cells into the lungs is, in turn, mounted by
these cytokines and chemokines [32] (Fig. 2). Although tissue-resi-
dent macrophages of the lungs localize to the airspace within alveoli,
they do not seem to be the predominant subset in this response [38].
Accumulation of inflammatory monocyte-macrophages and neutro-
phils in the lungs following SARS-CoV-2 infection promotes the addi-
tional release of cytokines and chemokines [32] (Fig. 2). Besides, the
SARS-CoV spike promotes the upregulation of IL-6 and tumor necro-
sis alpha (TNF-a) in macrophages[39].
Cytokines spill over from local inflammation to the systemic circu-
lation. COVID-19 patients have high serum levels of inflammatory
cytokines, including interleukin (IL)-2, IL-7, IL-10, granulocyte-colony
stimulating factor (G-CSF), interferon gamma-induced protein
(IP)-10, monocyte chemoattractant protein (MCP)-1, macrophager. The infected and surrounding pneumocytes secret cytokine and chemokines, which
al cytokines and chemokines. Ultimately the pneumocytes suffer apoptosis/pyroptosis
xpress adhesion molecules, and release chemokines and cytokines. Endothelial cells
nd breaks the alveolar-capillary barrier. The hyperinflammatory milieu and endothelial
n, and NETosis all of them promoting microcirculatory thrombi formation. The break of
lveolar space flooding. Downregulation of the ACE2/Ang-(17)/Mas1R axis contributes
e, and prothrombotic state.
s factor alpha; IL-10 = Interleukin 10; MCP-1 = Macrophage chemoattractant protein 1;
NF-KB = nuclear factor kappa B.
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kine levels correlate with disease severity [40,41]. COVID-19 patients
with severe disease have increased levels of IL-6 more often than
those with the mild or moderate disease [42]. Although viremia is
not a prominent feature in COVID-19 and is usually short-lived, the
degree and duration of SARS-CoV-2 viremia relates to the severity of
disease and the serum levels of IL-6 [43].
Endothelial cells (ECs) are infected very early in the course of
infection. Because of speedy viral replication and exuberant proin-
flammatory cytokine/chemokine response they may suffer apoptosis
[32,33]. This apoptotic phenomenon takes place via Fas/FasL or
TRAIL-DR-5-dependent mechanisms [44]. Besides, inflammatory
monocyte-macrophages release TNF-a which also promotes apopto-
sis of both lung ECs and AECs [35]. ECs and AECs apoptosis compro-
mise lung microvascular bed and alveolar cell-capillary barrier
integrity, thereby resulting in vascular leakage and alveolar edema
[35] (Fig. 2). Pericytes play an essential role in maintaining endothe-
lial cell function in capillary vessels and are among the cells with the
highest ACE2 expression. Their infection by SARS-CoV-2 may add to
endothelial cell dysfunction leading to microcirculation disorders
[29].
A striking feature of full-blown COVID-19 is severe lymphope-
nia. CoV-specific T-cells are decisive for viral clearance and limi-
tation of additional damage to host tissues since they can
dampen hyperreactive innate immune response [45,46]. However,
when exuberant inflammatory response induced by SARS-CoV-2
takes place, T-cell response is decreased because of TNF-a-medi-
ated cell apoptosis, thus resulting in uncontrolled inflammatory
responses [35] (Fig. 1). Besides, normal T-cell activation can be
suppressed by IL-6, further contributing to lymphopenia [47]. In
severe COVID-19 patients with lymphocyte subsets examined,
there is intense CD4 and particularly CD8 lymphopenia [42], both
negatively correlating with TNF-a and IL-6 serum levels [41]. CD4
cells promote the production of virus-specific antibodies by acti-
vating T-dependent B cells, whereas CD8 cells are cytotoxic and
can kill virus-infected cells. Since CD8 cells account for about 80%
of the total inflammatory lung interstitial infiltrate, highly cyto-
toxic CD8 lymphocytes can arbitrate immune-mediated tissue
damage [34]. Also, in COVID-19 patients, these cells exhibit
markers of functionally exhausted T-cells such as programmed
cell death protein 141.
There is upregulation of apoptosis, autophagy, and p53 pathways
in PBMC of COVID-19 patients [48]. MERS-CoV can induce T-cell
apoptosis through activation of the intrinsic and extrinsic apoptosis
pathways [49], and SARS-CoV E protein can also promote T-cell apo-
ptosis mediated by Cbl-XL binding [50]. Although SARS-CoV-2 can
non-productively infect T lymphocytes, whether this infection indu-
ces T-cell apoptosis is not yet clear [51]. Alternatively, pyroptosis
has been suggested as a cause of lymphopenia since COVID-19
patients have increased serum IL1-b levels, which is the down-
stream indicator of cell pyroptosis [52]. In SARS-CoV infection, viro-
porin 3a triggers the activation of NOD-like receptor protein 3
(NLRP3) inflammasome and the secretion of IL-1-b by macrophages
[53]. Pyroptosis can release large amounts of proinflammatory fac-
tors [54]. Whatever the cause, during the late stages of infection,
depletion of T-cells may promote viral survival and, consequently,
may prolong the infection.
Essential to control the persistent phase of SARS-CoV-2 infec-
tion is the appearance of humoral immunity, in which antiviral
neutralizing antibodies play a significant role. However, in animal
models, anti-S protein-neutralizing antibodies (anti-S-IgG) may
cause severe lung injury by altering inflammatory responses [55].
In SARS-CoV infection, the development of acute respiratory dis-
ease coincides with antiviral IgG seroconversion in 80% of
patients [56] and patients who died developed anti-S-neutralizing
antibodies faster [57]. The presence of anti-S-IgG promotesproinflammatory monocyte-macrophage lung accumulation and
the production of MCP-1 and IL-8. Such proinflammatory cytokine
release would be mediated through the binding of the virus-anti-
S-IgG complex to the monocytes-macrophages FcgRIIA receptor
since its blockade reduces the production of IFN-g , TNF-a, IL-1,
and IL-6 [55]. It would also be possible that such complexes acti-
vate the classical pathway of the complement system or induce
antibody-dependent cell-mediated cytotoxicity, thus leading to
cellular damage. Therefore, a possible underlying mechanism
would be antibody-dependent enhancement (ADE) of viral infec-
tion that occurs in some patients with early, sub-optimal anti-
body activity that cannot completely clear the virus, leading to
persistent viral replication and inflammation [58].
Uncontrolled viral replication, because of a delayed innate
immunity response, will cause cellular damage leading to an
overexuberant and dysregulated immune kickback. This hyper
reaction affecting the innate and adaptative immune responses
will pave the way for immune-mediated damage of tissues and
organs. This sequence of events conforms the inflammatory hurt-
ful feedback loop (Fig. 1).
4. The third horseman: a helpless lung
The RAS plays a critical role in the control of cardiovascular and
renal functions by maintaining blood pressure homeostasis and
hydro-electrolyte balance [59]. Initially, the RAS was conceived as a
linear hormonal system in which angiotensinogen synthesized in the
liver is converted into the active peptide angiotensin I (Ang I) through
the action of renin [60]. Afterward, Ang I is cleaved by the ACE gener-
ating Ang II [61]. Two G protein-coupled receptors (GPCR) mediate
the actions of Ang II, angiotensin II receptor type 1 (AT1R), and type 2
(AT2R) [62]. The primary role of this canonical or classical RAS path-
way (ACE/Ang II/AT1R) is to increase the sympathetic nervous system
tension, to cause vasoconstriction, increase blood pressure, and pro-
mote inflammation, fibrosis and myocardial hypertrophy [63].
The RAS also possesses a non-canonical, counter-regulatory
branch composed of ACE2/Ang-(17)/Mas1R. The activity of the sys-
tem will depend on the balance between the two branches. ACE2 is
the main synthesizer of Ang-(17) by removing a single residue from
Ang I to generate Ang-(19) and by cleaving a single residue from
Ang II to generate Ang-(17) [64,65]. The functional receptor for
Ang-(17) is the GPCR Mas1R [66]. The conformation of the negative
or counter-regulatory axis is relevant not only because it downgrades
the vasoconstrictive/ proliferative peptide Ang II to form the vasodi-
lator heptapeptide Ang-(17), but also because it degrades Ang I to
Ang-(19), thereby limiting the availability of the substrate for ACE.
Ang-(17) binds to Mas1R, inducing vasodilation, inhibition of cell
growth, anti-thrombotic, and anti-arrhythmogenic effects [67]. ACE2
activity is controlled by a disintegrin and metalloproteinase domain-
containing protein 17 (ADAM-17, also called TNF-a-converting
enzyme, TACE). ADAM-17 proteolytically cleaves ACE2 causing the
shedding of ACE2 into the interstitium, which leads to decreased
ACE2 activity in the tissue and elevates circulating ACE2 activity [68]
(Fig. 3). Since blood and urine measurement of ACE2 levels is feasible,
they could potentially be used as a prognostic biomarker in COVID-
19[69].
RAS plays an essential role in the pathogenesis of inflammatory
diseases in which most of the proinflammatory actions are caused by
Ang II [67]. Ang II activates several cellular functions and molecular
signaling pathways related to tissue injury, inflammation, and fibro-
sis. They involve calcium mobilization, free radical generation, activa-
tion of protein kinases and nuclear transcription factors, recruitment
of inflammatory cells, adhesion of monocyte and neutrophils to
endothelial and mesangial cells, upregulation of adhesion molecules
and stimulation of expression, synthesis, and release of cytokines and
chemokines [68]. AT1R mediates most of these actions [70]. The
Fig. 3. Implication of angiotensin-converting enzyme 2 (ACE2)/Angiotensin (Ang-17)/Mas1R in the pathogenesis of coronavirus disease 2019.
The lung, and other organs, lose the protection of the non-canonical RAS system as a result ACE2 downregulation after SARS-CoV-2-induced endocytosis. Consequently, the
canonical ACE/Ang II/AT1R becomes dominant, levels of Ang II increase with the subsequent promotion of fibrosis, myocardial hypertrophy, increased ROS, vasoconstriction, inflam-
mation, and endothelial dysfunction. AT1R mediates most of these actions. Endocytosed SARS-CoV-2 spike proteins mediates ADAM 17-mediated proteolytic cleavage of ACE2.
ADAM-17 activity is enhanced through the activated AT1R by increased levels of Ang II. TNF-a is the primary substrate of ADAM17. ADAM17 cleaves TNF-a releasing soluble TNF-a
extracellularly where it has autocrine and paracrine functionalities. Activation of TNF-a receptor by TNF-a also enhances ADAM17 activity.
ACE2 = Angiotensin-converting enzyme 2; SARS-CoV-2 = Severe acute respiratory syndrome coronavirus 2; Ang II = Angiotensin II; ROS = Reactive oxygen species;
AT1R = Angiotensin 1 receptor; ADAM17 = A disintegrin and metalloproteinase domain 17; TNF-a = Tumor necrosis factor alpha; TMPRSS2 = transmembrane protease serine 2.
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leukocyte migration, cytokine expression and release, and fibrogene-
sis pathways. Hence, ACE2 deficiency increases vascular inflamma-
tion by increasing the gene expression of vascular adhesion
molecules, cytokines, chemokines, and matrix metalloproteases [71].
The loss of ACE2 results in higher increases in Ang II-induced expres-
sion of inflammatory factors, enhanced vascular permeability,
increased lung edema, and neutrophil accumulation [72]. The ACE2/
Ang-(17)/Mas1R axis also plays an essential role in haemostasis,
since it stimulates prostacyclin (PGI2) production and nitric oxide
(NO) release by ECs and modulates platelet activity which is less
adherent having, thus anti-thrombotic activity [73] (Fig. 1).
RAS exhibits high activity in lung tissue, which is the leading site
of Ang II synthesis. ACE2 is a zinc metallopeptidase, type I integral
membrane glycoprotein orientated with the N-terminal, and the cat-
alytic site facing the extracellular space [74]. The union of ACE2 with
SARS viral spike protein triggers enzyme internalization downregu-
lating activity from the cell surface. Once SARS-CoV binds to its recep-
tor, the abundance on the cell surface, mRNA expression, and the
enzymatic activity of ACE2 are significantly reduced [75]. Proteolytic
shedding of its extracellular domain is a second mechanism for
downregulating ACE2 at the cell surface. S protein of SARS, once it
binds to ACE2, induces shedding by activating ADAM17 (TACE) as dobacterial endotoxin and lipopolysaccharide (LPS) [76] (Fig. 3). Releas-
ing ACE2 from the cell membrane is a critical step in catalyzing sub-
strates and implies that attenuation of ACE2 activity might
contribute to disease pathogenesis. The recently described induction
of ACE2 expression by type I IFN in human nasal epithelial cells, thus
behaving as an ISG, highlight an additional mechanism of ACE2
downregulation by SARS-CoV-2 [30]. Since IFN-induced ISGs are cru-
cial for host antiviral response, the absence of ACE2 induction due to
hampered IFN responses will further cause tissue unprotection.
Therefore, in COVID-19, ACE2 plays a pivotal role because of its multi-
faceted task as a facilitator of entry into AECs and its potential role in
the pathogenesis of acute lung injury (ALI) [75]. In the mouse model
of SARS, downregulation of ACE2 protein expression resulted in
worse pneumonia, increased Ang II levels, increased vascular perme-
ability, enhanced lung edema, neutrophil infiltration, and further
worsened lung function [72,77]. Catalytically active ACE2 protein
alleviated the symptoms, and active protein improved the outcome
of respiratory failure [72]. In COVID-19 patients, plasma concentra-
tions of Ang II were significantly higher than in healthy individuals
and Ang II levels correlated with viral load and lung injury [78].
Owing to the widespread expression of ACE2, COVID-19 is a dis-
seminated infection. ACE2 is highly expressed in the gut and SARS-
CoV-2 can productively infect enterocytes [28,79]. Despite ACE2
P. Domingo et al. / EBioMedicine 58 (2020) 102887 7expression in gut being higher than in the lung, only about 1012% of
patients with COVID-19 experience gastrointestinal symptoms [79].
The contribution of the digestive system to the pathogenesis of
COVID-19 through impairment of mucous membrane barrier and
increased inflammatory cytokine production has not been deter-
mined yet. Similar to MERS-CoV and owing to ACE2 expression in the
brush borders of the proximal tubules and in podocytes, kidney
injury in COVID-19 is characterized by diffuse proximal tubule dam-
age with virus-like particles in tubular epithelial cells and podocytes
which is indicative of direct SARS-CoV-2 infection [80]. These find-
ings translate clinically into acute kidney injury and proteinuria
which affect from 0.9% to 29% of COVID-19 patients [80].
The consequence of impaired ACE2 activity in the lung because of
SARS-CoV-2 infection is a reduction of Ang-(17) production. Ang-
(17) binding Mas1R promotes an array of biological responses to
counteract Ang II-mediated processes such as apoptosis, angiogene-
sis, vasoconstriction, and inflammation in the lung [81,82]. Conse-
quently, the attenuation of ACE2 catalytic function perturbs the
pulmonary RAS balance, resulting in enhanced inflammation and vas-
cular permeability, leaving the lung defenceless in the face of the
forthcoming raging cytokine storm. Besides, infection of type II pneu-
mocytes will reduce the production of alveolar surfactant subse-
quently reducing pulmonary elasticity. Moreover, the loss of type II
pneumocytes decreases restoration of type I pneumocytes which ulti-
mately impacts on gas exchange and fibrosis [83]. The above event
sequence depicts the RAS vicious feedback loop (Fig. 1).
5. The fourth horseman: an epidemic within the pandemic
The association between COVID-19 and coagulation disorders was
beheld early during the pandemic when Chinese physicians noticed
that patients treated mainly with low-molecular-weight heparin had
a decreased 28-day mortality [84]. This mortality improvement was
in patients with a sepsis score higher than four or a markedly ele-
vated D-dimer[84]. COVID-19 is associated with coagulation disor-
ders that include increases in procoagulant factors such as fibrinogen
and D-Dimers, both associated with poor prognosis [85,86]. Patients
admitted to the ICU had an increased incidence of venous thrombo-
embolic events ranging from 25% to 36% [87-89]. Moreover, standard
prophylaxis for venous thromboembolism failed in 7.7% of the
patients [90]. Some found that most thrombotic complications were
venous and primarily isolated pulmonary embolism, which suggests
that it may be primary pulmonary thrombosis instead of embolic
phenomena [89,91]. In line with that, microcirculatory thrombosis is
a constant finding in lung pathologic studies [33,34] (Fig. 2).
Infection of ECs, together with the derangements caused by cellu-
lar infiltration and high exposure to cytokines/chemokines, eventu-
ally leads to ECs dysfunction and apoptosis [33]. All of them
contribute to microvascular prothrombotic effects [92]. There is an
intense interplay between haemostasis and innate immunity, called
thrombo-inflammation [93]. Both the intrinsic and extrinsic coagula-
tion pathways can activate during inflammation. ECs and macro-
phages activate the extrinsic pathway through expression of tissue
factor [94]. The intrinsic pathway can be activated by neutrophil
extracellular traps (NETs) released by polymorphonuclear neutro-
phils (PMN) in a process called NETosis. NETs activate ECs, platelets,
and the complement system and release proteases that inactivate
endogenous anticoagulants [95]. However, the role of NETs in
COVID-19 is still a matter of discussion [96].
Platelets play a dual role. First, a proinflammatory role by secret-
ing alpha granules that recruit PMN and macrophages, which are an
essential source of IL-1b [97]. Besides, platelets stimulate PMN to
undergo NETosis which in turn activates platelets, creating a feed-
back loop. The second role of platelets is to activate the coagulation
pathway by assembling enzyme-cofactor-substrate complexes on
their exposed surface [98] (Fig. 1).Complement activation, which has been seen in the mouse model
of SARS, contributes to immune-mediated pathology [99]. Activation
of C3 and C5 promotes mast cell degranulation and recruitment of
PMN and macrophages [100]. The prothrombotic effects of activated
C3 and C5 include platelet and ECs activation, together with increas-
ing tissue factor and von Willebrand factor expression [95]. To close
the loop, thrombin, and other components of the coagulation cascade
can, in turn, activate C3 and C5 [95].
The primary function of thrombin is to promote clot formation by
activating platelets and by converting fibrinogen into fibrin [101].
However, thrombin is a pleiotropic molecule and can increase inflam-
mation via a proteinase-activated receptor (PAR), principally PAR-1
[101] (Fig. 1). The generation of thrombin is controlled by negative
feedback loops and physiological anticoagulants such as antithrom-
bin III, tissue factor pathway inhibitor and the protein C system
[101]. IL-1b, IL-6, and TNF-a promote the release of ultra-large von
Willebrand multimers, and the production of tissue factor and factor
VII/activated factor VII, leading to increased thrombin generation
while decreasing the levels of endogenous anticoagulants [101].
The ACE2/Ang-(17)/Mas1R axis exerts antithrombotic effects
through activation of Mas1R in platelets, which then release NO and
PGI2 and by protecting from endothelial dysfunction [102,103]. Since
this branch of the RAS is not working properly in COVID-19, this pro-
tective mechanism is lost (Figs. 1 and 3).
In severe COVID-19, similar to other acute viral infections, a high
prevalence od antiphospholipid antibodies was found, although the
role of these antibodies in the prothrombotic state of SAR-CoV-2-
infected patients is still a matter of debate [104].
The progression of thrombo-inflammation may result in wide-
spread thrombosis, which may be further enhanced by hypoxemia,
hyperthermia, and hypovolemia [105]. Hypoxemia triggers increased
expression of hypoxia-inducible factors, which may promote addi-
tional inflammation and may activate platelets and coagulation fac-
tors. They increase tissue factor expression, increase plasminogen
activating inhibitor-1, and inhibit the endogenous anticoagulant pro-
tein S [106]. In the setting of a hyperinflammatory state and endothe-
lial injury, activation of coagulation occurs whereas the counter-
regulatory force ACE2/Ang-(17)/Mas1R axis is inactive, leaving the
field to the full expression of a hypercoagulable state. This state may
clinically translate into pulmonary thrombosis, venous thromboem-
bolism, or other thrombotic events. If these events affect microvascu-
lar lung bed, they may further promote ALI and impair gas exchange.
Whatever the location of the thrombotic event is, it worsens the
patient’s prognosis.
Hyperinflammatory state and defective ACE2/Ang-(17)/Mas1R
functioning activate the fourth hurtful feedback loop. Hyperinflam-
mation induces hypercoagulation and vice versa, while ACE2/Ang-
(17)/Mas1R axis avoidance maximizes both (Fig. 1).6. A broad scale of damage
The clinical spectrum of COVID-19 is broad. Not everyone who
acquires SARS- CoV-2 becomes sick and the state that emerges after
infection can vary among patients or within the same patient over
time. Consequently, it is envisaged that virus-dependent, host-
dependent, and environment-dependent factors may modify the
virus-host interaction explaining not only the individual susceptibil-
ity to infection but also the broad scale of damage seen in clinical dis-
ease.
The initial viral titre in the airways could explain the different
evolving patterns of COVID-19, since this will condition the intensity
of cytopathic changes, which in turn will shape the strength of
immune responses [35]. SARS-CoV-2 replicates in high numbers very
early after infection, and in turn, the magnitude of viral replication
will impact on the extent of antiviral response [27]. In humans, there
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disease severity [35].
In animal models, the disease behaves differently if the virus
infects airway epithelial cells or both airway and AECs (type I and
type II pneumocytes) predominantly. The viral antigen is mainly
located in airway epithelial cells in mouse models permissible to
infection, but which do not develop clinical disease. In contrast, in
highly susceptible mice, the antigen is detected in both airways and
alveolar type I and II pneumocytes [35]. Consequently, infection of
AECs seems critical for both host susceptibility and the development
of lung pathology. An aspect that influences SARS-CoV-2 infection is
the state of differentiation of human airway epithelia, which, in turn,
correlates positively with the expression level of ACE2 in these cells
[107,108]. It is noteworthy that ACE2 nasal gene expression is lower
in children [109]. This fact is connected to the striking age distribu-
tion of COVID-19 in which children are often spared, affecting adults
with enhanced severity and mortality as age increases [5,47]. How-
ever, the increasingly poor outcome with advancing age is influenced
by the presence of common comorbidities, such as hypertension, car-
diovascular disease, and diabetes, which bear a poor prognosis by
themselves [47]. Besides, these comorbidities relate to a decreased
activity of ACE2 in elderly patients, a deficit further exacerbated by
SARS-CoV-2 infection [110]. ADE is a potentially harmful, pro-inflam-
matory mechanism which occurs when suboptimal titres of neutral-
izing antibodies against SARS-CoV-2 are present. They are unable to
control infection but instead facilitate viral entry into macrophages
by a Trojan horse mechanism. ADE tends to happen when the time
interval between coronavirus infections is long enough for antibody
fall, which could be a possible mechanism for severe COVID-19 in the
aged [58].
Females with COVID-19 usually present with milder disease than
males. Females exhibit higher IFN and IFN regulator factor and IL-10
production from PBMC, lower production of TNF-a, lower expression
of TLR4 in PMN, lower numbers of NK cells, and lower PMN phago-
cytic activity than males [111]. Oestrogens downregulate Ang II and
upregulate Ang-(17) pathways, which makes apparent gender dif-
ferences in expression, activity, and tissue responsiveness of RAS
components [112]. Besides, Mas1R expression was increased in
female rats but not in males after the infusion of Ang II [113]. In ani-
mal models of obesity, females appear to maintain circulating Ang-
(17) levels and are protected from hypertension and metabolic
complications induced by angiotensinogen, renin, angiotensin II, and
AT1R activation [114]. Stimulation of counterregulatory AT2R
appears metabolically protective in female rodents, whilst there are
inconsistent effects in males [115].
In the UK, 72% of COVID-19 patients in the ICU were either over-
weight or obese [116], and 99% of dead North Italians had obesity,
hypertension, diabetes, heart disease, kidney damage, or cancer
[117]. The frequent occurrence of obesity as a factor of adverse out-
come is frequently shadowed by other high prevalent comorbidities
in obese people making the identification of the independent role of
obesity steep [118]. The association of COVID-19 with obesity has
been attributed to the chronic inflammatory status, the ineffective
immune response or to interaction with the RAS system.
The immune pathways are all susceptible to genetic polymor-
phisms with functional consequences such as variability in cytokine
expression, antigen-binding affinities, receptor ligation strength, and
downstream signaling [119,120]. High interconnection is a promi-
nent feature of immune pathways and thus functional resultant poly-
morphisms may hamper the growth of an optimal immune response
to COVID-19. Responses triggered by PAMPs recognition and its
downstream molecules such as myeloid differentiation primary
response 88 (MDY88) may be altered by TLR polymorphisms
[121,122]. HLA genes present extreme allelic polymorphism. Since
they present viral peptides to host HLA molecules to trigger an adap-
tative immune response, their polymorphisms may causeunevenness in antigen binding and presentation, and consequently
in immune response. HLA-B*46:01 has been associated to the devel-
opment and increased severity of SARS-CoV [123], and it has the few-
est predicted binding affinity of SARS-Cov-2 peptides [124]. IL-6
plays a central role in the hyperactive immune response in COVID-19
patients. Since there are functional polymorphisms in the IL-6 gene
that modify its protein level expression, they may affect the severity
of the disease [125]. The role of RAS in the pathogenesis of COVID-19
is essential. Single nucleotide polymorphisms and haplotypes in ACE
genes, such as polymorphism A/D in the ACE1 gene, have been asso-
ciated with circulating and tissue concentrations of ACE levels and
reduced expression of ACE2 [126,127]. Interestingly, the prevalence
of COVID-19 in Europe correlates inversely with ACE D allele fre-
quency [127]. A genetic variant of the IFN-induced transmembrane
protein-3 gene is associated with COVID-19 severity. IFN-induced
transmembrane protein-3 is an immune effector protein that acts
restricting membrane fusion [128]. Recently, a genomewide associa-
tion study in COVID-19 patients with respiratory failure identified an
association signal at locus 3p21.31, which includes the genes
SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6 and XCR1, while there was no
association signals at the HLA complex [129].
Lately, there has been a contention about the beneficial or det-
rimental role of ACE inhibitors (ACEi) and angiotensin receptor
blockers (ARB) in the outcome of patients with COVID-19. Cur-
rently, there is no evidence to support an advantageous or harm-
ful effect of concomitant therapy with ACEi or ARB in COVID-19
patients [130].
7. Pathogenetically-based therapeutic insights
COVID-19 is a systemic infection since it may impact any tissue or
organ expressing ACE2. However, the most dreadful, often life-
threatening conditions, are ALI and ARDS. Therefore, the main chal-
lenge is to avoid their development to prevent ICU admission and
mechanical ventilatory support. We could envisage COVID-19 as a
tree in which AECs viral infection and ACE2 downregulation repre-
sent the roots. The tree trunk would be the hyperinflammatory and
hypercoagulable state. The branches would be an end-organ disease,
such as ALI, myocarditis, neurological disease, liver injury, gastroin-
testinal involvement, and skin disease.
Since the chain of events triggered by SARS-CoV-2 infection
evolves quickly, any planned intervention must come as early as pos-
sible. Besides, since the pathogenesis of COVID-19 involves non-viral
mechanisms, any intervention planned must also address the correc-
tion or modulation of these disbalances. Hence, any therapeutic inter-
vention must be early and combine antiviral and adjuvant therapies.
However, the moment of diagnosis and eventual hospital admission
will mark the timeframe of interventions.
To tackle the roots of the disease, potential therapeutic interven-
tions for COVID-19 should first address the viral entry into AECs. The
entry of SARS-CoV-2 into AECs takes place after binding of the spike
to the receptor ACE2. Specifically, the binding takes place in the
receptor-binding domain of the S protein. Thus, developing neutraliz-
ing monoclonal antibodies for this domain is a rational strategy to
prevent the viral union and subsequent events [131]. Another possi-
ble way of targeting the interaction between ACE2 and S protein may
be the use of soluble recombinant ACE2, which may prevent the
binding of the viral particle to the surface-bound, full-length ACE2
[132]. In the Vero-E6 monkey cell line, a soluble form of ACE2 blocks
SARS-CoV replication and reduced SARS-CoV-2 recovery by a factor
of 10005000 [132,133]. Besides, since SARS-CoV-2 downregulates
the ACE2/Ang-(17)/Mas1R axis, recombinant human ACE2 (rhACE2)
could prevent the development of ALI in COVID-19. rhACE2 attenu-
ated arterial hypoxemia in a piglet model of LPS-induced ALI [134]. In
phase II, open-label trial in humans with ARDS rhACE2 was well tol-
erated, Ang II levels decreased, whereas Ang-(17) and surfactant
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detect changes in acute physiological or clinical outcomes [135].
There is a randomized controlled trial to assess rhACE2 in patients
with severe COVID-19 (NCT 04287686). Apart from ACE2, SARS-CoV-
2 entry involves TMPRSS2, whose inhibitor, camostat mesylate, sig-
nificantly reduced lung cell line infection with SARS-CoV-2 [136].
Endocytosis is a crucial step in SARS-CoV-2 infection. AP-2-associ-
ated protein kinase (AAK1) regulates this process [137]. Baricitinib, a
Janus-kinase inhibitor, has been claimed as a candidate drug for
COVID-19 since it inhibits AAK1 [138]. Arbidol inhibits viral entry by
inhibiting the fusion between viral and cellular membranes [139].
However, in a small retrospective study, arbidol did not meet non-
inferiority versus the combination of arbidol and lopinavir/ritonavir
(LPV/r) [140]. Chloroquine and its safer derivative hydroxychloro-
quine are effective against SARS-CoV-2 in vitro [141]. However,
recent news from the large Recovery trial showed that there is no
beneficial effect of hydroxychloroquine in patients hospitalised with
COVID-19; therefore, that arm of the study was stopped [142]. Other
planned large trials, such as Solidarity, stopped enrolling patients to
the hydroxychloroquine arm, and the National Institutes of Health-
sponsored ORCHID study was also stopped [143,144].
Numerous antivirals agents are being tested in clinical trials. LPV/r
could not demonstrate enough efficacy when compared with placebo
[145]. The combination of IFN, LPV/r, and ribavirin showed a shorter
time to negativize nasopharyngeal swabs and superiority versus LPV/
r in alleviating symptoms [146]. In two double-blind, placebo-con-
trolled trials, remdesivir was not associated with statistically signifi-
cant clinical benefits in one, whereas in the other shortened the time
to recovery in hospitalized adults [147,148]. As of now, there is no
antiviral drug with proven efficacy for treating patients with COVID-
19.
Another strategy tries to modulate the exuberant inflammatory
response in COVID-19. The use of corticosteroids is controversial and
not supported by previous experience in SARS and MERS [149]. How-
ever, in the Recovery trial, dexamethasone reduced deaths by one
third in patients receiving invasive mechanical ventilation and by
one fifth in patients receiving oxygen without invasive mechanical
ventilation [150]. Tocilizumab, a specific IL-6 receptor antagonist, is
promoted to treat the hyperinflammatory state of COVID-19 because
of the pathogenic role IL-6 plays. Two observational studies have
shown a clinical benefit of therapy with tocilizumab in COVID-19
pneumonia with hyperinflammatory syndrome [151,152]. Anakinra,
a recombinant IL-1 receptor antagonist, has proven useful in a small
retrospective study of COVID-19 patients with ARDS and hyper
inflammation [153]. There are additional trials in progress with tocili-
zumab, anakinra, and sarilumab. However, when trying to modify the
cytokine response by targeting a single molecule or receptor, it
should be recalled that the cytokine network is an intricate complex
with a high degree of overlap, redundancy, and alternate pathways.
This may explain therapy escape and eventually lack of response.
Therapeutic interventions for the consequences of hyperinflam-
matory and hypercoagulable states associated with COVID-19, such
as ALI, ARDS or thromboembolic events, are beyond this review's
scope.
8. Conclusions
Knowledge of pathophysiology is the first step to address the
management of a disease appropriately. It is familiar with the mecha-
nism that the virus uses to evade host immune defense mechanisms
or those that uses to harm will permit the design of appropriate strat-
egies to neutralize the dysfunctions or disbalances generated either
by the virus or by the consequences of the infection. From the knowl-
edge gathered, it seems that most organ damage in severe COVID-19
is done through an immune-mediated mechanism, although SARS-
CoV-2 is the necessary initiator. The spectrum of disease iscomprehensive, and since not all the patients will share the same
evolving pattern, the search for predictive factors to promptly iden-
tify patients more prone to evolve to life-threatening disease is of the
utmost importance. In severe cases, the quick evolving pattern of the
disease makes early treatment imperative, at least until reliable pre-
dictive factors become widely available. The implication of viral and
host-dependent mechanisms in COVID-19 pathogenesis suggests
that any therapeutic strategy must combine antiviral drugs and adju-
vant therapy to modulate the host’s responses.
All these goals will be achieved through the broad effort of basic,
translational, and clinical scientists and clinicians, and will demand a
high degree of commitment from patients and their families, allied
professionals, and everyone engaged in the fight against COVID-19.
Among them, politicians and Health Administration Officers will play
a unique role, since such a gigantic task will need the allocation of a
vast amount of resources to overcome a health challenge to Mankind
like none other in recent times.
9. Outstanding questions
While engrossed amid the pandemic, there was progress on the
physiopathology of COVID-19. However, gaps regarding viral, envi-
ronmental, and transmissibility aspects remain—the dynamic inter-
play between the host and the virus and how to modify it to improve
disease prognosis not being the lesser.
There is a big difference in transmissibility, which is highest for
SARS-CoV-2, among b-coronaviruses despite similar structure and
functioning. Asymptomatic viral shedding is the main factor. How-
ever, the role of newly described ORFs and RNA modifications and
their functional correlations are not evident yet. Although TMPRSS2
is involved in viral entry into the host cell, the involvement of other
host proteins is still under discussion.
The role of the different epithelial cells along the bronchial tree
and the alveolar space needs to be ascertained. The virus's mecha-
nisms to invade other organs beyond the lung are already poorly
known.
Clinical disease progression is somewhat unpredictable. There-
fore, the identification of prognostic clinical and biological markers
would optimize patients' care and resource consumption, which may
be of utmost importance in pandemic times. This effort must include
which role comorbidities and gender play. The definition and timing
of the optimal therapeutic approach to COVID-19 will represent a
colossal effort, which can be accomplished only by randomized clini-
cal trial performance. These should include concerted actions and a
combination of diverse disciplines, resources, expertise, and techni-
ques to contribute to advances in prevention, diagnosis, and therapy.
This set makes up an almost flawless meaning of translational medi-
cine defined by the European Society for Translational Medicine
(EUSTM) as "an interdisciplinary branch of the biomedical field sup-
ported by three main pillars: benchside, bedside, and community."
10. Search strategy and selection criteria
For this Review, our search strategy involved the review of origi-
nal records, either journals or books, mainly from European and
American sources, from1984 to 2020. From these sources, we hand
searched reference lists of identified additional articles to retrieve
additional studies. Preference was given to most relevant research,
but we were also keen to highlight the breadth of the topic and hence
selected some publications that showcase particular areas of interest.
We have searched PubMed and Google Scholar from database
inception to May 21, 2020, for records, journals, and books for the
terms “SARS-CoV-200, “COVID-1900, “Coronavirus”, “RAAS system”,
“angiotensin-converting enzyme”, “angiotensin-converting enzyme
200, “cytokine storm”, “cytokine”, “chemokine”, “acute lung injury”,
“adult respiratory distress syndrome”, “interferon”, “interleukin ”,
10 P. Domingo et al. / EBioMedicine 58 (2020) 102887“Middle East respiratory syndrome”, and “Severe acute respiratory
syndrome”. References were examined in English.
Declaration of Competing Interest
We declare no competing interests.
Contributors
The concept of the manuscript was devised by PD who also per-
formed the overall literature searches. IM, VP, HC, and JC designed
the search strategy with inputs from PD and NdB. IM, VP, HC, and JC
carried out the literature searches and screening, and any discrepan-
cies were discussed with PD and NdB. PD wrote the first draft of the
review with inputs from all the authors.
Funding
This work was partially supported by grant COV20/00070. Insti-
tuto de Salud Carlos III, Madrid, Spain. The funding source was not
involved in the design of the study or in writing the report. All
authors had access to the data used in the analyses, and the lead
author reviewed the full report. The full study data were available to
all authors. PD, NdB made the decision to submit the paper for publi-
cation.
Acknowledgments
We are indebted to Jordi Mancebo and M Antonia Mangues for
critical reading of the manuscript, and to Richard Pike for reviewing
its writing.
References
[1] WHO. Novel coronavirus China. Jan 12, 2020. http://www.who.int/csr/don/12-
january-2020-novel-coronavirus-china/en/ (accessed May 20, 2020).
[2] Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019
novel coronavirus: implications for virus origins and receptor binding. Lancet
2020;395:565–74.
[3] Johns Hopkins. https://coronavirus.jhu.edu/map.html
[4] Mason RJ. Pathogenesis of COVID-19 from a cell biologic perspective. Eur Respir J
2020;55:2000607.
[5] Wu Z, McGoogan JM. Characteristics of and important lessons from the corona-
virus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314
cases from the Chinese Center for Disease Control and Prevention. JAMA 2020
[Online ahead of print]. doi: 10.1001/jama.2020.2648.
[6] Pirofski LA, Casadevall A. The damage-response framework as a tool for the phy-
sician-scientist to understand the pathogenesis of infectious diseases. J Infect
Dis 2018;218(Suppl 1):S7–S11.
[7] Kim D, Lee JY, Yang JS, KIM JW, Kim VN, Chang H. The architecture of SARS-CoV-
2 transcriptome. Cell 2020;181:914–21.
[8] Masters PS. Themolecular biology of coronaviruses. Adv Virus Res 2006;66:193–292.
[9] Knoops K, Kikkert M, Worm SH, et al. SARS-coronavirus replication is supported
by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol
2008;6:e226.
[10] Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagno-
sis of COVID-19. J Pharm Anal 2020;10:102–8.
[11] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new
coronavirus of probable bat origin. Nature 2020;579:270–3.
[12] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a func-
tional receptor for the SARS coronavirus. Nature 2003;426:450–4.
[13] de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights
into emerging coronaviruses. Nat Rev Microbiol 2016;14:523–34.
[14] Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory
disease in China. Nature 2020;579:265–9.
[15] Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike
protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad
Sci USA 2009;106:5871–6.
[16] Perlman S, Netland J. Coronaviruses post-SARS: update on replication and path-
ogenesis. Nat Rev Microbiol 2009;7:439–50.
[17] Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med
Virol 2020;92:424–32.
[18] Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, et al. Ultrastructure and origin
of membrane vesicles associated with the severe acute respiratory syndrome
coronavirus replication complex. J Virol 2006;80:5927–40.[19] Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe
acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by
sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi
membrane. J Virol 2007;81:9812–24.
[20] Kindler E, Thiel V, Weber F. Interaction of SARS and MERS coronaviruses with
the antiviral interferon response. Adv Virus Res 2016;96:219–43.
[21] Narayanan K, Huang C, Lokugamage K, et al. Severe acute respiratory syndrome
coronavirus nsp1 suppresses host gene expression, including that of type I inter-
feron, in infected cells. J Virol 2008;82:4471–9.
[22] Sun L, Xing Y, Chen X, et al. Coronavirus papain-like proteases negatively regu-
late antiviral innate immune response through disruption of STING-mediated
signaling. PLoS One 2012;7:e30802.
[23] Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infec-
tion. Cytokine Growth Factor Rev 2008;19:121–32.
[24] Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune
responses and viral antagonism of interferon. Curr Opin Virol 2012;2:264–75.
[25] Fehr AR, Channappanavar R, Jankevicius G, et al. The conserved coronavirus
macrodomain promotes virulence and suppresses the innate immune response
during severe acute respiratory syndrome coronavirus infection. mBio 2016;7
e01721-16.
[26] Siu KL, Chan CP, Kok KH, Chiu-Yat Woo P, Jin DY. Suppression of innate antiviral
response by severe acute respiratory syndrome coronavirus M protein is mediated
through the first transmembrane domain. Cell Mol Immunol 2014;11:141–9.
[27] Chu H, Chan JF, Wang Y, et al. Comparative replication and immune activation
profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with
implications for the pathogenesis of COVID-19. Clin Infect Dis 2020 [Online
ahead of print]. doi: 10.1093/cid/ciaa410.
[28] Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distri-
bution of ACE2 protein, the functional receptor for SARS coronavirus. A first step
in understanding SARS pathogenesis. J Pathol 2004;203:631–7.
[29] Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indi-
cates new potential mechanism of heart injury among patients infected with
SARS-CoV-2. Cardiovasc Res 2020;116:1097–100.
[30] Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an inter-
feron-stimulated gene in human airway epithelial cells and is detected in spe-
cific cell Subsets across tissues. Cell 2020;181:1016–35 e19.
[31] W€olfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
patients with COVID-2019. Nature 2020;581:465–9.
[32] Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and
inflammatory monocyte-macrophage responses cause lethal pneumonia in
SARS-CoV-infected mice. Cell Host Microbe 2016;19:181–93.
[33] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis
in COVID-19. Lancet 2020;395:1417–8.
[34] Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliali-
tis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020 [Online ahead
of print]. doi: 10.1056/NEJMoa2015432.
[35] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes
and consequences of cytokine storm and immunopathology. Semin Immunopa-
thol 2017;39:529–39.
[36] He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory
cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the
acute lung injury and pathogenesis of SARS. J Pathol 2006;210:288–97.
[37] Zhang X, Wu K, Wang D, et al. Nucleocapsid protein of SARS-CoV activates inter-
leukin-6 expression through cellular transcription factor NF-kappa B. Virology
2007;365:324–35.
[38] Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells
in patients with COVID-19. Nat Med 2020;26:842–4.
[39] Wang W, Ye L, Ye L, et al. Up-regulation of IL-6 and TNF-alpha induced by SARS-
coronavirus spike protein in murine macrophages via NF-kappa B pathway.
Virus Res 2007;128:1–8.
[40] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
[41] Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in
patients with coronavirus disease 2019 (COVID-19). Front Immunol 2020
[Online ahead of print]. doi: 10.3389/fimmu.2020.00827.
[42] Wan S, Yi Q, Fan S, Lv J, et al. Relationships among lymphocyte subsets, cyto-
kines, and the pulmonary inflammation index in coronavirus (COVID-19)
infected patients. Br J Haematol 2020;189:428–37.
[43] Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia)
is closely correlated with drastically elevated interleukin 6 (IL-6) level in criti-
cally ill COVID-19 patients. Clin Infect Dis 2020 [Online ahead of print]. doi:
10.1093/cid/ciaa449.
[44] Rodrigue-Gervais IG, Labbe K, Dagenais M, et al. Cellular inhibitor of apo-
ptosis protein cIAP2 protects against pulmonary tissue necrosis during
influenza virus infection to promote host survival. Cell Host Microbe
2014;15:23–35.
[45] Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clini-
cal disease and for virus clearance in severe acute respiratory syndrome corona-
virus-infected mice. J Virol 2010;84:9318–25.
[46] Kim KD, Zhao J, Auh S, et al. Adaptive immune cells temper initial innate
responses. Nat Med 2007;13:1248–52.
[47] GuanWJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in
China. N Engl J Med 2020;382:1708–20.
[48] Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar
lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.
Emerg Microbes Infect 2020;9:761–70.
P. Domingo et al. / EBioMedicine 58 (2020) 102887 11[49] Mubarak A, Alturaiki W, Hemida MG. Middle east respiratory syndrome corona-
virus (MERS-CoV): infection, immunological response, and vaccine develop-
ment. J Immunol Res 2019;2019 6491738-11.
[50] Yang Y, Xiong Z, Zhang S, et al. Bcl-xL inhibits T-cell apoptosis induced by
expression of SARS coronavirus E protein in the absence of growth factors. Bio-
chem J 2005;392(Pt 1):135–43.
[51] Wang X, Xu W, Hu G, et al. SARS-CoV-2 infects T lymphocytes through its spike
protein-mediated membrane fusion. Cell Mol Immunol 2020 [Online ahead of
print]. doi: 10.1038/s41423-020-0424-9.
[52] Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV Infec-
tion (2020). Available at SSRN: http://dx.doi.org/10.2139/ssrn.3527420
[53] Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome
coronavirus Viroporin 3a activates the NLRP3 inflammasome. Front Microbiol
2019;10:50.
[54] Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to
osmotic lysis of infected hostmacrophages. Cell Microbiol 2006;8:1812–25.
[55] Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skew-
ing macrophage responses during acute SARS-CoV infection. JCI Insight 2019;4:
e123158.
[56] Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a com-
munity outbreak of coronavirus-associated SARS pneumonia: a prospective
study. Lancet 2003;361:1767–72.
[57] Zhang L, Zhang F, YuW, et al. Antibody responses against SARS coronavirus are corre-
latedwith disease outcome of infected individuals. J Med Virol 2006;78:1–8.
[58] Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in
COVID-19. Nat Rev Immunol 2020;20:339–41.
[59] Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS
axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev
2018;98:505–53.
[60] Guyton AC. Kidneys and fluids in pressure regulation. Small volume but large
pressure changes. Hypertension 1992;19(Suppl. 1):12–8.
[61] Kokubu T, Ueda E, Joh T, Nishimura K. Purification and properties of angiotensin
I-converting enzyme in human lung and its role on the metabolism of vasoactive
peptides in pulmonary circulation. Adv Exp Med Biol 1979;120B:467–75.
[62] Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol
Res 2002;35:1001–15 2002.
[63] Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and patho-
logical effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:
C82–97.
[64] Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-
related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ
Res 2000;87:E1–9.
[65] Douglas GC, O'Bryan MK, Hedger MP, et al. The novel angiotensin-converting
enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of
the testis. Endocrinology 2004;145:4703–11.
[66] Santos RA, Haibara AS, Campagnole-Santos MJ, et al. Characterization of a new
selective antagonist for angiotensin-(1-7), D-pro7-angiotensin-(1-7). Hyperten-
sion 2003;41(3 Pt 2):737–43.
[67] Silva ACS, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and
Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013;169:
477–92.
[68] Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 axis of
the renin-angiotensin system in heart failure. Circ Res 2016;118:1313–26.
[69] Liu MY, Liu MY, Zheng B, Zhang Y, Li JP. Role and mechanism of angiotensin-con-
verting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Dis
Transl Med 2020;6:98–105.
[70] Capettini LS, Montecucco F, Mach F, Stergiopulos N, Santos RA, da Silva RF. Role
of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm
Des 2012;18:963–70.
[71] Thomas MC, Pickering RJ, Tsorotes D, et al. (2010). Genetic Ace2 deficiency
accentuates vascular inflammation and atherosclerosis in the ApoE knockout
mouse. Circ Res 2010;107:888–97.
[72] Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from
severe acute lung failure. Nature 2005;436:112–6.
[73] Fraga-Silva RA, Da Silva DG, Montecucco F, et al. The angiotensin-converting
enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating
thrombotic diseases. Thromb Haemost 2012;108:1089–96.
[74] Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physi-
ology and disease. J Pathol 2007;212:1–11.
[75] Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory
lung disease. Shock 2016;46:239–48.
[76] Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-con-
verting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha
production and facilitates viral entry. Proc Natl Acad Sci USA 2008;105:
7809–14.
[77] Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2
(ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875–89.
[78] Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV
infected patients linked to viral loads and lung injury. Sci China Life Sci
2020;63:364–74.
[79] Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of gastrointesti-
nal symptoms and fecal viral shedding in patients with coronavirus disease
2019: a systematic review and meta-analysis. JAMA Netw Open 2020;3:
e2011335.
[80] Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem
findings of patients with COVID-19 in China. Kidney Int 2020;98:219–27.[81] Gaddam RR, Chambers S, Bhatia M. ACE and ACE2 in inflammation: a tale of two
enzymes. Inflamm Allergy Drug Targets 2014;13:224–34.
[82] Bader M. ACE2, angiotensin-(1-7), and Mas: the other side of the coin. Pfl€ug Arch
2013;465:79–85.
[83] Walls Ac, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the
SARS_CoV-2 glycoprotein. Cell 2020;181:281–92 e6.
[84] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated
with decreased mortality in severe coronavirus disease 2019 patients with coa-
gulopathy. J Thromb Haemost 2020;18:1094–9.
[85] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
2020;395:1054–62.
[86] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients
with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA
2020;323:1061–9.
[87] Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complica-
tions in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.
[88] Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in
patients with severe novel coronavirus pneumonia. J Thromb Haemost
2020;18:1421–4 2020.
[89] Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic
complications in COVID-19 patients admitted to an academic hospital in Milan,
Italy. Thromb Res 2020;191:9–14.
[90] Lim W, Meade M, Lauzier F, et al. Failure of anticoagulant thromboprophylaxis:
risk factors in medical-surgical critically ill patients* multicenter study; random-
ized controlled trial. Crit Care Med 2015;43:401–10.
[91] Marongiu F, Mameli A, Grandone E, Barcellona D. Pulmonary thrombosis: a clini-
cal pathological entity distinct from pulmonary embolism? Semin Thromb
Hemost 2019;45:778–83.
[92] Beristain-Covarrubias N, Perez-Toledo M, Thomas MR, Henderson IR, Watson SP,
Cunningham AF. Understanding infection-induced thrombosis: lessons learned
from animal models. Front Immunol 2019;10:2569.
[93] Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of
COVID-19. J Thromb Haemost 2020 [Online ahead of print]. doi: 10.1111/
jth.14849.
[94] Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: chal-
lenges of therapeutically targeting coagulation and other host defense mecha-
nisms. Blood 2019;133:906–18.
[95] Keragala CB, Draxler DF,McQuilten ZK,Medcalf RL. Haemostasis and innate immunity
- a complementary relationship: a review of the intricate relationship between coagu-
lation and complement pathways. Br J Haematol 2018;180:782–98.
[96] Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of
COVID-19: neutrophil extracellular traps. J Exp Med 2020;217:e20200652.
[97] Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coro-
navirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta
2020;506:145–8.
[98] Walsh PN. Platelet coagulation-protein interactions. Semin Thromb Hemost
2004;30:461–71.
[99] Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes
to severe acute respiratory syndrome coronavirus pathogenesis. mBio 2018;9
e01753-18.
[100] Fogari R, Zoppi A, Mugellini A, Maffioli P, Lazzari P, Derosa G. Role of angiotensin
II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive
patients with metabolic syndrome. Hypertens Res 2011;34:1321–6.
[101] Jose RJ, Williams AE, Chambers RC. Proteinase-activated receptors in fibroproli-
ferative lung disease. Thorax 2014;69:190–2.
[102] Fang C, Stavrou E, Schmaier AA, et al. Angiotensin 1-7 and Mas decrease throm-
bosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet
spreading and glycoprotein VI activation. Blood 2013;121:3023–32.
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